Despite its benefits, REACH poses challenges, particularly for small and medium-sized enterprises (SMEs) due to the high costs and complexity associated with compliance. The extensive data requirements can be burdensome, necessitating significant financial and technical resources. Moreover, the need for alternative methods to reduce animal testing remains a critical challenge, as these methods may not yet fully replicate the results of traditional toxicological assessments.
